8-K: Gain Therapeutics Unveils GT-02287 Parkinson's Data

Gain Therapeutics hosted a Key Opinion Leader event to discuss emerging data from its Phase 1b study of GT-02287 for Parkinson's Disease, highlighting safety and initial efficacy trends.

Summary

• Gain Therapeutics, Inc. (GANX) hosted a virtual Key Opinion Leader (KOL) event on October 14, 2025, focusing on its investigational drug GT-02287 for Parkinson's Disease (PD).
• The event featured KOLs Karl Kieburtz, M.D., M.P.H., and Kenneth Marek, M.D., discussing biomarkers, clinical endpoints, and disease modification in PD.
• GT-02287 is designed to correct protein misfolding and restore glucocerebrosidase (GCase) enzymatic activity, addressing a key mechanism in GBA1-Parkinson's Disease.
• Preclinical models demonstrated GT-02287's broad neuroprotective effects, including reduced ER stress, restored lysosomal and mitochondrial function, and depletion of toxic substrates and alpha-synuclein.
• The Phase 1b open-label study enrolled 21 participants with PD (with or without a pathogenic GBA1 mutation) between March and September 2025.
• Initial Phase 1b data showed GT-02287 was generally well-tolerated, with 85% of treatment-emergent adverse events (TEAEs) being mild.
• Plasma exposures of GT-02287 were within the projected therapeutic range and comparable to those observed in healthy volunteers.
• MDS-UPDRS scores showed no mean improvement by Day 30 but a mean improvement by Day 90, suggesting a slower, non-acute symptomatic effect.
• A reduction of 1-2 points on UPDRS Part II and 4-8 points on Part III is considered clinically meaningful.

Sentiment

Score: 7

Explanation: The filing presents initial Phase 1b data for GT-02287, showing a favorable safety and tolerability profile and plasma pharmacokinetics within the therapeutic range. While no acute symptomatic effect was observed, a mean improvement in MDS-UPDRS scores by Day 90 suggests a potential slower, disease-modifying effect, which is a positive signal for a neurodegenerative drug. The clear roadmap for future development (IND filing, Phase 2a) adds to the positive outlook, despite the early stage of the data.

Positives

• GT-02287 demonstrated a broad neuroprotective effect in preclinical models, including reduced ER stress, restored lysosomal and mitochondrial function, and depletion of toxic substrates and alpha-synuclein.
• The Phase 1b study showed GT-02287 to be generally well-tolerated, with 85% of treatment-emergent adverse events (TEAEs) being mild and no treatment-emergent serious adverse events (SAEs).
• Plasma concentrations of GT-02287 were within the projected therapeutic range and consistent with observations in healthy volunteers.
• Initial Phase 1b data indicated a mean improvement in MDS-UPDRS scores by Day 90, suggesting a potential slower, disease-modifying effect, which is relevant for neurodegenerative diseases.

Negatives

• No acute, dopaminergic, symptomatic effect was observed in MDS-UPDRS scores by Day 30.
• Common treatment-emergent adverse events included headache (6 participants), lab abnormalities (6 participants), diarrhea (6 participants), fatigue (4 participants), and nausea (3 participants).
• One participant discontinued the study after 24 days due to panic attacks, nausea, and headaches.
• Three participants required dose reductions or interruptions due to adverse events, including constipation, transient increases in liver enzymes (ALT, ALP, GGT), and transient increase in lipase.

Risks

• The company's ability to develop, obtain regulatory approval for, and commercialize its product candidates.
• The timing of future IND submissions, initiation of preclinical studies and clinical trials, and timing of expected clinical results for product candidates.
• Success in early preclinical studies may not be indicative of results obtained in later studies or clinical trials.
• The potential benefits of product candidates may not be realized.
• The company's ability to obtain regulatory approval to commercialize existing or future product candidates.
• The company's ability to identify patients with the diseases treated by product candidates and to enroll patients in clinical trials.
• The success of efforts to expand the pipeline of product candidates and develop marketable products through the use of the Magellan platform.
• The company's expectations regarding collaborations and other agreements with third parties and their potential benefits.
• The company's ability to obtain, maintain, and protect intellectual property.
• Reliance upon intellectual property licensed from third parties, including the license to use the Magellan platform.
• The company's ability to identify, recruit, and retain key personnel.
• The company's financial performance.
• Developments or projections relating to competitors or the industry.
• The impact of laws and regulations.
• The company's expectations regarding the time during which it will be an emerging growth company under the JOBS Act.

Future Outlook

The company expects to file an Investigational New Drug (IND) application by the end of 2025 and initiate a Phase 2a study in Parkinson's patients in the first half of 2026. Updates on Phase 1b results will be available throughout the first half of 2026, with final results from the Phase 1b study extension anticipated in the second half of 2026. These next steps are designed to further demonstrate GT-02287's safety, target engagement, broader neuroprotective effect substantiated by biomarker changes, and potential for stabilization or slowing of disease progression.

Management Comments

• Gene Mack, President & CEO of Gain Therapeutics, provided opening comments and an overview of Parkinson's Disease and the Phase 1b study of GT-02287.
• Jonas Hannestad, M.D., Chief Medical Officer of Gain Therapeutics, presented an overview of the recent Phase 1b data for GT-02287.

Industry Context

Parkinson's Disease is the second most common neurodegenerative disease, affecting over 1 million patients in the U.S., with current therapies primarily treating symptoms rather than preventing disease progression. GBA1 mutations represent the largest genetic risk factor for PD, leading to earlier onset and more severe disease, highlighting a significant unmet need for disease-modifying therapies in this subpopulation. The industry is increasingly focused on biomarkers for early detection, disease progression assessment, and targeted treatment in slowly progressive, heterogeneous neurodegenerative disorders, moving towards a biologic definition of Neuronal Synuclein Disease (NSD).

Comparison to Industry Standards

• The Parkinson Progression Marker Initiative (PPMI) is a large-scale, multi-center international study (N=5500 participants) focused on identifying biomarkers for NSD/PD progression, utilizing a comprehensive set of core biomarkers (aSyn SAA, DAT imaging, WGS) and targeted neurodegeneration analytes (NFL, GFAP, p-tau 217, AB40/42, p-tau 181).
• Ongoing clinical trials by companies like Roche and Biohaven are utilizing MDS-UPDRS scores in time-to-event analyses, defining worsening (e.g., 5 points in Part III or 2 points in Part II) as an event in early to mid-stage PD.
• The alpha-synuclein imaging landscape in 2025 includes several tracers in development or human trials, such as [18F]ACI-12589 (AC Immune), [11C]MK-7337 (Merck), [11C]MODAG-005 (Tuebingen), [18F]FD4 (Shanghai group), [11C]SY-08 (Massachusetts General Hospital), [18F]SPAL-T-06 (National Institutes for Quantum Science and Technology), and [18F]C05-05, indicating active research in objective alpha-synuclein pathology detection.

Stakeholder Impact

• Shareholders: The initial positive safety and tolerability data, coupled with a potential slower efficacy signal and clear development roadmap, could positively influence investor confidence and future valuation.
• Patients with Parkinson's Disease: The development of GT-02287 offers hope for a disease-modifying therapy, particularly for the GBA1-PD subpopulation, which currently lacks such treatments.
• Medical Community: The KOL event and emerging data contribute to the scientific understanding of Parkinson's Disease and the potential role of GCase activators, fostering further research and discussion.

Next Steps

• Full 90-day analysis of functional changes scored according to MDS-UPDRS and biomarker activity in cerebrospinal fluid and blood for participants enrolled through June 30, 2025.
• IND filing expected by end of 2025.
• Initiation of Phase 2a study in Parkinson's patients in the first half of 2026.
• Updates on Phase 1b study results will be available throughout the first half of 2026.
• Final results from the Phase 1b study extension expected in the second half of 2026.

Key Dates

Recommendation

The initial Phase 1b data for GT-02287 shows a good safety profile and promising preclinical neuroprotective effects. While the MDS-UPDRS data suggests a slower, non-acute effect, which is reasonable for a disease-modifying drug in Parkinson's, it is still very early-stage clinical data. Significant milestones, including IND filing and Phase 2a initiation, are upcoming. A 'hold' recommendation is appropriate for a seasoned investor, acknowledging the positive early signals and future potential, but also the inherent risks and uncertainties of drug development at this stage, awaiting more definitive efficacy data from larger trials.

Keywords

Gain Therapeutics, GANX, Parkinson's Disease, GT-02287, GBA1, Neurodegenerative, Clinical Trial, Phase 1b, Biomarkers, KOL Event, MDS-UPDRS, Glucocerebrosidase